Showing posts with label Alzheimer's. Show all posts
Showing posts with label Alzheimer's. Show all posts

Thursday, 9 April 2015

Michael Mullan Research Scientist at Roskamp

Dr. Michael Mullan is distinguished face of biomedical science. He is widely known for his research work for Swedish mutation present in familial form. He is well known for his developmental work in therapeutic cures for Alzheimer’s disease. His arrays of interests have always been neuroscience, drug development, cognitive development, brain health and neuropsychiatric diseases.

Dr. Michael Mullan Dr. Mullan acquired his initial education in 1984 from the Royal Free School of Medicine where he was also positioned as the President of the Royal Free Mental Handicap Society. After graduating, he practiced as a Surgeon and later on took the position in psychiatry at Friar Hospital in London. Subsequently to further increase his experience he joined Middlesex Hospital Medical School where he was positioned as a researcher in Molecular Genetic Study of Alzheimer’s disease. It was from there that he kept on developing interest and desire to find a cure for this disease. Dr. Mullan has also served as an Honorary Clinical Research Registrar at St. Mary’s Hospital and The National Hospital for Nervous Diseases. In 1992, Dr. Mullan joined University of South Florida and thus established Roskamp Laboratories. In 2003, Roskamp Institute relocated to Sarasota, Florida where Dr. Mullan served as the Director and conducted various researches on Alzheimer’s disease. 

Dr. Michael Mullan in association with his colleague Dr. Fiona Crawford made the discovery of Swedish mutation and let to find the initial cause of the Alzheimer’sdisease. They together had created the first animal model for Alzheimer’s disease. His major research works includes investigating the role of beta amyloid in inflammation and determining the CD40-CD40L signaling pathways associated with Alzheimer’s disease pathogenesis. He has acquired several patents to his name and numerous publications. 

Serving at directorial positions of various organizations, he is currently the CEO and Chairman of the Board of Rockcreek Pharmaceuticals. As the founder of Roskamp institute in Sarasota, Florida, Dr. Mullan’s leadership led to cutting edge development in neuropsychiatric illnesses. His research work was funded by multiple agencies including the NIH and the Department of defense. 

Dr. Michael Mullan works mainly on Alzheimer’s disease but he is just not limited till there. He has served for finding cures in childhood metal illness and disorders like Tourette’s syndrome, Autism, Gulf war illness, Traumatic Brain Injury and Drug Addiction. His work in the field of biomedical research is very noticeable. He has served for the betterment of a vast majority of the community. Most of patients of Alzheimer’s disease are the elderly 60 plus. And preserving the life experiences is one contribution of his for the nation. Many patients reminisce about their past and it is very hard to see them with fading memories. Patients suffering from Alzheimer’s disease face the most traumatic loss as they keep forgetting their recent past as well as their family and friends. Dr. Mullan’s work has tremendously contributed towards developing FDA approved drugs for such patients and new developments are still going on at the Roskamp institute in Florida.

To successfully cure neuropsychiatric diseases and promote healthy aging, Dr. Michael Mullan founded the Roskamp Institute with the same mission and to conduct safe and effective drug therapies. He has been a successful figure in the biomedical science and is achieving great heights in his work.

Friday, 13 March 2015

Roskamp Institute – Attempting Alzheimer through Objective Researches

Health is a gift for the mind, body and soul and is the true wealth to cherish. However, this gifted wealth often gets aberrated due to disease conditions. If the person is lucky enough, then he can get cured with the available line of drugs; however, there are certain illnesses, the cures for which have remained elusive after long and dedicated researches.
Dr. Michael MullanAlzheimer disease is characterized by most of the dementia symptoms such as the memory degradation, visual losses, locomotor losses and identification problems among others. The pitiful aspect of Alzheimer is that most of the symptoms and manifestations are sidelined as that of old age in a very commonly accepted norm, thus leaving the aged person to struggle. The more educated and aware societies of the world have shown greater rates of diagnosis, if not the incidence.
Finding out the fundamental factors
The med community has been engaged in quality and deeper researches so as to establish the reasons, but the cure is still far away. There have been some authentic insight, of course, from some noted quarters like the Roskamp Institute of US. This not for profit research institute has under the inspiring leadership of Michael Mullan produced valuable leads as for understanding some correlations between Alzheimer and associated factors.
Dr Mullan is considered a global authority on Alzheimer research because of his pioneering studies that helped establish the role of beta amyloid protein which he found is overproduced due to a genetic inconsistency. Greater the production of this protein, greater would be the progression rate of the disease.
 Running associated programs for holistic research
Michael Mullan is the CEO of Sarasota based Roskamp Institute and has been guiding the next phase of the researches to bring out more insights through dedicated programs of direct consonances. The institute runs its ‘Vision Research Program’ that is oriented towards studying the visual impairments in the dementia and Alzheimer by studying the patterns of visual cortex and optical nerves over the time in the Alzheimer patients.
The Institute also runs Memory Clinics where objective counseling is offered with the aim of arresting the disease progression. The Roskamp Institute also studies the effect of the potential risk factors as for Alzheimer disease such as the head injuries, family history, depression and hypertension among others. Such correlations have proved to be beneficial as for prescribing the care suggestions for the person where already the onset has been diagnosed.
Carrying out effective yet ethical clinical trials -
The research maneuvers of the Institute are complemented by the ‘Clinical Trials Division’ of it which is an attempt to collect the most authentic of the databases from the willing volunteers in an ethical manner. The volunteers are offered potential cures free of cost together with effective cushioning against the side effects.
 Michael Mullan has established some of the finest standards in this Sarasota institute which is escorting the care and cure attempts with the best of the Biomedical Researcher community at its end. The findings of this Institute have been validated by noted journals that demonstrate the efficacies.

Wednesday, 4 February 2015

Michael Mullan, The World's Leading Neuroscientist

A lot of research has been going on in the field of Alzheimer's and brain development. And, one of the leading institutes doing this research is Roskamp Institute. Based out of Sarasota in United States, is an non-profit organization, which is committed towards discovering and treating neuropsychiatric as well as neuro-degenerative disorders.

Michael Mullan happens to be the director of this prestigious institute. Dr. Mullan was born in 1956 in Kent. He did his graduation in Medicine and Surgery from London University. He did his post-graduation in Psychiatry from Royal college in 1990. Then, he did his PhD in Philosophy, specializing in Molecular Genetics from London University, in the year 1993.
Michael MullanCareer of Dr. Mullan:
Michael began his career in the year 1988 and worked for 3 years in a major teaching hospital in London named The Royal Free Hospital. Then, he worked as senior registrar with the Psychiatric hospital named Friern Hospital. He has also worked as Professor for Biological Psychiatry, and professor in Department of Neurology and Pathology. He is the CEO of Roskamp-Institute in Florida currently. He has been the main person behind the research on Alzheimer's disease. He holds around 12 patents in total. And, he has published about 200 scientific studies in the past 3 decades. And, all these published materials are on Alzheimer's disease, neuropathy of dementia, molecular genetics, manic-depression, alcoholism, schizophrenia, etc. He has received a number of awards and honours for all his research work.

Dr. Mullan is the bio-medical researcher of Beta Amyloid Protein. And, he has been working on its relation with Alzheimer's disease. His research is quite well known in the bio-medical community. Due to his research, Swiss Mutation has been identified. The transgenic animals for the Alzheimer's makes use of the Swedish Mutation. The institute, which is headed by Dr. Mullan and Dr. Fiona Crawford, has been dedicated towards the research. The institute has various experienced scientists, technicians and the most-updated equipment and tools for conducting the scientific research. And, the research quality is also the best. As per them, better science leads to a real discovery. The mission of this institute is conducting the scientific research so that safer and more effective drugs can be taken out for treating the mind-related diseases. 

The Roskamp institute in Sarasota has a wide range of technical innovative advancements. And, under the leadership of Dr. Mullan, there are about 70 clinicians, scientists, students, and other administrative staff, who work together for pursuing the research so that the source of the neurological disorders can be found out. And, once the cause is found out, the future treatments can be devised. The institute is dedicated towards discovering safe and effective drug therapies. With the help of these therapies, the aging can happen in an healthy manner.

With the efforts of Dr. Mullan, the Neuroscientist, there has been a lot of work towards improvement of the diagnosis of Alzheimer's patients. So, anybody, who is suffering from a disease of the mind, can find the appropriate help and guidance from here.

Friday, 16 January 2015

Alzheimer – Memory Loss that can Lead to Death

Alzheimer is a disease which has surfaced more during the recent years. It is caused by the protein compounds that are accumulated in the brain. Since it is a neuro-degenerative disease, the person gets worse as time passes by. The disease is recognized by the early onset of short term memory loss. This can lead to death as the functions of the body are lost one at a time.

Alzheimer
There are many medical institutes that are researching on the Alzheimer’s disease. The researchers believe that it is mostly caused by genetic disorder. Michael Mullan is one of the most popular researchers who studied the cause and cure of Alzheimer. He is well trained in molecular genetics to perform gene research with respect to the disease. He currently holds the position of President and CEO in Roskamp Institute which is located in Florida. Dr.Mullan made ground breaking research and presented over 200 articles on Alzheimer which also includes the treatment for the disease.

Dr. Mullan having experience of more than 20 years in biotechnology, invented patents that used APP mutations. He worked for the causes of this disease along with its cure by receiving grants from federal organizations. He was the first person to identify the genetic cause of the disease. It was established that people with gene mutations present in TREM2 had a higher risk of getting affected by the Alzheimer disease.
There are medications which can help in treating the patients and can slow down the progress of Alzheimer, but a sure cure for the disease is still a work under progress. Roskamp is the closest institute which is on the way to finding a cure. The drug, Nilvadipine, was administered for treating hypertension, which is identified as one of the reasons that cause the disease. This drug has been proved to stop the protein production in the brain. Amyloid is considered to be a tombstone and hence the drug was developed to stop its production all together.

Michael Mullan Roskamp Institute diagnoses patients with Alzheimer and offer clinical trial for the drug which was developed. Observations were made in the genes and the medical history of the relatives in order to diagnose the disease. Medical imaging like MRI and PET are used to rule out other forms of dementia. This type of diagnosis can be made only after the onset of the disease. Early diagnosis include cerebrospinal fluid test for the presence of amyloid. This spinal tap predicts the onset of the disease which is about 94% accurate. 

There is no drug at present to prevent the onset of this disease. But, various studies prove that measures like dieting, intellectual activities and reducing cholesterol level can be done to decrease the chance of being affected by Alzheimer’s disease.

Tuesday, 2 December 2014

Understanding the Possibilities of Curing Alzheimer Disease


Medical Treatment
It is a fact that presently, there exists no medicine for treating Alzheimer disease. At the same time, it is not possible to prevent the disease or have effective treatments for it. However, there are present few non-drug and drug treatments, which do provide relief on a temporary basis for both cognitive and behavioral symptoms.

Cholinesterase Inhibitors
These are known to assist in preserving the capability of the sick nerve endings for transmitting nerve messages to next cell present in chain.

Alzheimer's Disease

Neurotransmitter Acetylcholine
In regards to this disease, one of the most vital neurotransmitter is said to be acetylcholine (which is actually a very small blip of chemical that diffuses quite rapidly across junctions of the nerve cell for stimulating the next cell), which is utilized by nerve cells in brain part to think and for memory making. At the same time, it is equally essential that acetylcholine gets eliminated at the earliest after the message has been carried across junction. In case, it is not, then it is likely to keep on stimulating downstream cell. It can be disastrous, while leading to possible attacks.

Disturbance in Degradation Process
Generally, acetylcholine gets destroyed instantly after delivering the message by an enzyme known as cholinesterase. In Alzheimer’s, nerve cell endings could get much sicker and acetylcholine amount that is produced by every nerve impulse could get lesser and lesser with the progress of the disease.

What does Cholinesterase Inhibitors do?
Cholinesterase inhibitors which are utilized as Alzheimer’s cure might restrain destroying by cholinesterase of acetylcholine, which results in acetylcholine level getting high enough for getting the message over the next cell.

Temporary Solution
However, this would not work forever. Over a period of time, sick nerve endings tend to start degenerating and withdrawing from junctions. The messages not longer could be transferred. Generally, it takes around 2 to 3 years before the situation gets reached (occasionally it tends to last much longer). It explains as to why cholinesterase inhibitors generally work on a temporary basis.

Researching on Treatment of the Disease
Scientists at Sarasota camp are continuing with the research for coming up with treatments that are effective and for holding the disease off, quickly. By researching on the web, one can get few examples. Article regards to Nature Genetics does mention identification of more five genes behind this disease by a research consortium.

The experts at Michael Mullan have been trying to come up with researches for understanding the events which leads towards damage of bigger brain parts and eventually complete loss of the cognitive abilities. According to a published article in a leading Journal, insulin can have a new, powerful role to fight the disease. The article describes new clinical researches done by the experts that found that low insulin dose is found to suppress successfully the expression in blood of 4 precursor proteins that are involve in pathogenesis of the disease.

The roskamp institute states that it has been working on to come up with novel cures having the capability to slow down the progression rate of the disease and try to eradicate it in the near future.

For More Details Visit Here: Michael Mullan

Tuesday, 14 January 2014

Alzheimer’s disease – Treatment Approaches That Work


Thousands of people around the world suffer from the crippling effects of Alzheimer’s disease. This is a disorder where the part of the brain that controls memory is affected. Several research institutions around the world are trying their best to find a cure to this disease. Michael Mullan has been a pioneer in this field. His research on the dreaded disease is well known throughout the world.

The identification of a certain protein that has got a direct relation to the onset of the disease has been a significant discovery of Dr. Michael Mullan. A biomedical researcher, Dr.Mullan is considered an authority when it comes to research on mental disorders. His career started after he received his medical degree from the London University. He trained as a physician in England. He has completed his PhD in molecular genetics, again from the London University. He has been the key figure behind over 200 papers on Alzheimer’s disease. At present, as the CEO and President of The Roskamp Institute, located in Sarasota, Florida, he is further continuing his crusade against this debilitating disorder.



One of the significant findings of the researchers at The Roskamp Institute is that of the “Brain Reserve Index”. Using this index the researchers are able to indicate the risk of developing Alzheimer’s disease in a person. Dr. Mullan’s research papers are much sought after by the medical community around the world.

Apart from the work that is being done by Dr. Mullan, there are other research institutions around the world which also have been trying to find a cure to the disease. While significant breakthroughs have been made, there is no known cure for Alzheimer’s disease till now. The disease is known to becoming increasingly progressive as a person ages. A group of drugs known as “cholinesterase inhibitors” are usually used for treating the condition. What these drugs do is to moderate the symptoms. In certain cases, doctors also recommend anti-psychotic medicines for people suffering from the disease.

The team under Dr. Mullan at Sarasota, Florida has also done a lot of research on the link between diet and the onset of Alzheimer’s disease. Accordingly they have figured out that certain types of diet are beneficial in preventing the onset of the disease in the first place. A well balanced diet that consists of plenty of fresh fruits and vegetables to provide all the necessary vitamins and minerals has been recommended to tackle the menace of Alzheimer’s disease.



Thursday, 12 December 2013

Well Known Researcher Calls for More Studies on Alzheimer’s Disease


 
There are a few diseases that have puzzled medical researchers for long and one of them is Alzheimer’s Disease. According to conservative estimates, more than 36 million people across the globe suffer from this disease. As a matter of fact, there is growing concern about this disease which tends to mostly affect elderly people given that populations of many countries are aging rapidly. This is sure to put a lot of pressure on public health care systems in many countries while also resulting in societal problems unless a vaccine or a cure for it can be found.

According to widely famed scientist and biomedical researcher Dr.Micheal Mullen, one of the biggest problems is that this disease does not get the attention that it deserves even though it poses huge problems. As President and CEO of the Roskamp Institute which is located in Sarasota Florida, he leads a team of dedicated researchers who have been at the forefront of the research to understand this disease. He certainly knows what he is talking about when he says that the disease needs to be understood better. Dr. Mullen, a physician trained in London, is also a renowned geneticist who has published many papers on Alzheimer’s and other long term degenerative diseases that affect the brain.

One of the biggest problems faced by Alzheimer’s researchers is the serious lack of funding. This has got something to do with the fact that trials for this disease take inordinately long. It is an unfortunate fact that the cost of the trials goes up in direct proportion to the time it takes. In fact, there are at least a hundred trails for cancer for every trial conducted for Alzheimer's disease. Besides, clinical trials for this disease are not easy to conduct.



Another factor to be considered is that most research on Alzheimer’s focuses on the levels of a protein called Amyloid in late stage Alzheimer’s patients. It is the accumulation of this protein in the brain which is known to cause the onset of the disease. However, since very little research studies its levels at the early stages or even before the onset of the disease, there is still very little understanding of the disease. Michael Mullan has maintained that this small but significant protein merits further study as do other early markers of Alzheimer’s disease.

There is absolutely no doubt about the fact that the Alzheimer’s research community is woefully underfunded. It is only when it gets government and private funding in the required quantum that researchers will be able to get plenty of breakthroughs about this disease. In the meanwhile, physicians and researchers alike eagerly await the results of studies conducted at places like the Roskamp Institute.